Naimish Patel's most recent trade in CRISPR Therapeutics AG was a trade of 25,000 Restricted Stock Units done . Disclosure was reported to the exchange on May 30, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| CRISPR Therapeutics AG | Naimish Patel | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2025 | 25,000 | 25,000 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | Naimish Patel | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 May 2025 | 10,000 | 30,000 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | Naimish Patel | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 May 2025 | 10,000 | 10,000 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | Naimish Patel | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 35.94 per share. | 28 May 2025 | 3,932 | 6,068 (0%) | 0% | 35.9 | 141,316 | Common Shares |
| CRISPR Therapeutics AG | Naimish Patel | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2025 | 46,667 | 46,667 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | Naimish Patel | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2025 | 32,500 | 32,500 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | Naimish Patel | Chief Medical Officer | 16 Oct 2024 | 18,333 | 18,333 | - | - | Stock Option (Right to Buy) | ||
| CRISPR Therapeutics AG | Naimish Patel | Chief Medical Officer | 28 May 2024 | 85,000 | 85,000 | - | - | Stock Option (Right to Buy) | ||
| CRISPR Therapeutics AG | Naimish Patel | Chief Medical Officer | 28 May 2024 | 40,000 | 40,000 | - | - | Restricted Stock Units |